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D. Perrea4 and A.G. Kostakis112nd Department of Propedeutic Surgery, Laikon Hospital, 23rd Department of Surgery, Attikon Hospital,
Athens University Medical School, 3Vascular Surgery Department, Sismanogleion Hospital, and 4Laboratory
of Experimental Surgery and Surgical Research ‘N Christeas’,
Athens University Medical School, Athens, GreeceBackground. Our aim was to investigate the association of inflammation and Chlamydia pneumoniae infection with the
presence and severity of peripheral arterial disease.
Methods. Twenty-eight patients whose initial claudication distance (ICD) in the traditional constant-load treadmill test
was!200 m, underwent femoral endarterectomy as part of their interventional treatment (group A). Group B consisted of
23 patients whose ICD wasO200 m and were put on medication and a daily exercise program. The control group consisted
of 30 non-vascular patients of the Ophthalmology Department (group C). We measured the levels of C-reactive protein,
fibrinogen, vascular cell adhesion molecule-1 and tumor necrosis factor-a, and the titers of IgA and IgG antibodies against C.
pneumoniae in the serum of all the patients. Finally, the atheromas and vein segments of group A patients, were
immunohistochemically (IHC) examined for the presence of C. pneumoniae.
Results. Peripheral arterial disease (PAD) patients, had significantly higher CRP (pZ0.026) and anti-Cp IgA levels (pZ
0.001) when compared to control subjects, after a multiple linear regression analysis. The odds ratio for the prevalence of
femoral atherosclerosis was 3.16 for IgA seropositive patients (CI 1.15–8.67). When comparing group A and group B
patients, CRP (pZ0.003) and IgA (pZ0.011), were significantly correlated with severe PAD. Group A patients with
positive immunohistochemical examination of the plaque, had higher anti-Cp IgA levels (pZ0.023) and TNF-a values (pZ
0.031), compared to the IHC negative patients. C. pneumoniae was detected in 50% of the femoral atheromas, but in only
3.6% of the veins.
Conclusion. This study supports the hypothesis that inflammation (CRP) and chronic C. pneumoniae infection (IgA
seropositivity), have an important role in lower limb atherosclerosis and correlate with the severity of the disease.Keywords: Inflammation; Inflammatory markers; Infection; C. pneumoniae; Atherosclerosis; Peripheral arterial disease;
Claudication.Introduction
Sir William Osler was the first to talk about the
involvement of inflammation and infection in the
pathogenesis of atherosclerosis, almost a 100 years
ago.1 Inflammation has now been shown to contribute
fundamentally to atherogenesis.2 The role of inflam-
mation and Chlamydia pneumoniae in the development
of coronary artery and cerebrovascular disease has
been thoroughly studied.3–5
Peripheral arterial disease affects a large part of
the general population, with a prevalence of
intermittent claudication of 3–7%.6 It is aing author. Elias A. Kaperonis, MD, 85, G. Zografou Str.,
, Greece.
: pepperon7@hotmail.com
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this is clearly shown by the high prevalence of
coexistent coronary and cerebral arterial disease in
these patients.7 Serum levels of inflammatory
markers, have been found to be higher in patients
with peripheral arterial disease (PAD)8 than in
controls. Others, have found a high C. pneumoniae
seropositivity rate and have frequently detected the
pathogen in the femoral atheromatous plaques9 of
PAD patients. Although, quite recently anti-chlamy-
dial antibiotic therapy has been shown to inhibit
progression of PAD,10 in the large antibiotic trials,11
treatment had no beneficial effect on coronary artery
disease patients.
In this cross-sectional study, we examined the
relationship of serum levels of inflammatory markersEur J Vasc Endovasc Surg 31, 509–515 (2006)
doi:10.1016/j.ejvs.2005.11.022, available online at http://www.sciencedirect.com onved.
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molecule-1 and tumor necrosis factor-a), serum titers
of anti-C. pneumoniae antibodies (IgA and IgG) and C.
pneumoniae isolation in femoral atheroma, with per-
ipheral arterial disease. The hypothesis that these
variables, not only are associated with lower limb
atherosclerosis, but might also be linked to the severity
of the disease has not been tested previously.Methods
Only patients with intermittent claudication were
eligible for the study. Patients with critical limb
ischemia were excluded. Diagnosis of PAD, was
established with ABI measurement and lower limb
duplex US scans. Twenty-eight patients who had an
initial claudication distance less than 200 m in the
constant load treadmill test, and underwent femoral
endarterectomy as part of their interventional treat-
ment in the Vascular Surgery Department between
January 2003 and December 2003 were included in
group A. On US all but one (96.4%) had multilevel
disease. Endarterectomy was usually an adjunct to an
aortobifem, fem–fem, fem–pop, fem–distal by-pass (25
patients) or iliac stenting (two patients). Only in one
patient was femoral endarterectomy the only treat-
ment. The 23 patients of group B, had an initial
claudication distance O200 m, and were treated
conservatively (medication and exercise). Fifteen of
them (65.2%) had multilevel disease on ultrasound.
The control group (group C), consisted of 30 patients
of the Ophthalmology Department, who did not have
any clinical, laboratory or imaging findings of
atherosclerosis. All control subjects had ABI greater
than 0.90. The study was approved by the hospital
ethics committee, and informed consent was obtained
from all participants. Exclusion criteria for all groups
were the presence of chronic or active inflammatory or
infectious disease, malignancy, systematic adminis-
tration (O3 days) of anti-inflammatory drugs, anti-
biotics or corticosteroids, and pathologic basic
inflammation markers (WBC count and ESR value).
All patients in groups A and B had lower limb arterial
duplex US scans and patients in group A had also an
abdominal aorta and lower limb DSA preoperatively.
At entry into the study a complete medical history
was taken and risk factors were recorded, including
age, gender, coronary artery disease (CAD; angina
pectoris, myocardial infarction, coronary artery by-
pass grafting, percutaneous transluminal coronary
angioplasty), diabetes mellitus (controlled with diet,
oral hypoglycemic agents or insulin; fasting glucose
level O7 mmol/l), hypercholesterolemia (on statinEur J Vasc Endovasc Surg Vol 31, May 2006therapy; total cholesterolO5.2 mmol/l), hypertension
(on anti-hypertensive treatment; blood pressure O
160 mmHg systolic or 95 mmHg diastolic) and smok-
ing history (current or past). Height and weight were
measured and body mass index (BMI) was calculated
in all patients.
Baseline assessment included measurement of
ankle/brachial systolic pressure index (ABI). Systemic
blood pressure in both arms and ankles was measured
using a hand held Doppler device (8 MHz; Huntleigh
Doppler, Cardiff, Wales) and a standard mercury
sphygmomanometer, in all patients. The constant
load treadmill test was performed at a velocity of
3 km/h and a 10% slope. Two familiarization sessions
preceded the actual test and they were all done in three
consecutive days by the same observer.
Upon entry into the study, venous blood samples
were obtained for the determination of CRP, fibrino-
gen, vascular cell adhesion molecule-1 (VCAM-1) and
tumor necrosis factor-a (TNF-a) levels in the serum as
well as for the measurement of IgA and IgG anti-Cp
titers and the samples were immediately stored at
K70 8C and analyzed at the end of the study.
CRP levels were measured by the photometric–
turbidimetric test for the quantitative determination of
human hs-CRP in serum and plasma (Human,
Wiesbaden, Germany). Fibrinogen was measured
using the photometric method. Soluble VCAM-1
serum values were determined using the sVCAM-1
ELISA (IBL, Hamburg, Germany). TNF-a levels were
calculated by the titerzyme enzyme immunometric
assay of human TNF-a (Assay Designs Inc., Michigan,
USA). The antibodies used, do not show significant
cross-reactivity with other known cytokines. The IgA
and IgG anti-Cp titers were determined via the
quantitative ELISA technique (Immunolisa, Orgenics,
Israel). They were measured in Enzyme ImmunoU-
nits/ml, and positivity was appointed to values O
5 EIU/ml. All samples were assayed in duplicate by
technicians blind to clinical information.
Femoral plaques as well as saphenofemoral junc-
tion branch vein segments, were sliced and four
sections for each patient were kept in deep freeze
(K70 8C) until the end of the study. The presence of C.
pneumoniae on the specimen was detected with the
immunohistochemical technique (IHC), using the
monoclonal antibody to C. pneumoniae of Biogenex,
USA. The technique was considered positive when cell
groups and not isolated cells were stained positively in
at least three out of four sections. Pathologists were
also unaware of the clinical data of the patients.
In the statistical analysis, continuous variables are
expressed as meanGSD and categorical variables are
presented as percentages. Comparisons of continuous
Table 2. Baseline characteristics of group A and B patients
Group A
(nZ28)
Group B
(nZ23)
p
Age (years) 71.6G7.6 68.0G6.5 NS
Male gender (%) 82.1 86.9 NS
Hypertension (%) 75 69.6 NS
CAD (%) 50 47.8 NS
Hypercholesterolemia (%) 35.7 34.8 NS
Diabetes mellitus (%) 42.9 26.1 NS
Smoking (%) 67.9 78.3 NS
Body mass index (kg/m2) 28G3.3 27.5G2.7 NS
Ankle–brachial index 0.33G0.15 0.64G0.08 !0.001
ICD (m) 96.8G61.8 269.1G43 !0.001
ACD (m) 136.4G97.4 410.4G89.2 !0.001
Statin use (%) 28.6 30.4 NS
Values are meanGSD or percentages.
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Pearson parametric or the Spearman non-parametric
test, as appropriate. The t-test or the Mann–Whitney
U-test were used, as appropriate, for pair-wise
comparisons between the groups of interest. Associ-
ations between two categorical variables were tested
by the c2-test or the Fisher’s exact test, as appropriate.
After determining univariate associations, multivari-
ate analysis (multiple linear regression analysis) was
used to determine independence of associations. All
tests were two-tailed and p!0.05 was considered
significant. All the analyses were done with the SPSS
statistical software (v9.0, SPSS Inc., Chicago, Illinois,
USA).Results
The basic clinical characteristics of PAD patients
(groups A and B) and non-vascular control patients
are shown on Table 1. Coronary artery disease,
diabetes mellitus, hyperlipidemia, smoking and statin
use were significantly more common and ABI
significantly lower among patients with peripheral
arterial occlusive disease. Groups A and B patients
had no significant difference in age, gender, the
traditional risk factors for atherosclerosis, body mass
index and statin use (Table 2). The differences in ABI,
initial claudication distance (ICD) and absolute
claudication distance (ACD) are expected since
patients were enrolled in the groups on the basis of
their ICD.
Table 3 summarizes data of PAD patients and
control subjects, regarding the levels of the inflamma-
tory markers and the anti-Cp antibodies studied. CRP
concentrations were significantly higher in the PAD
group (groups A and B) than in the controls (pZ0.001).
Almost two thirds of the CRP values in group C were
below 1 mg/dl, whereas in PAD patients, two out ofTable 1. Baseline characteristics of control subjects vs. PAD
patients
Control
subjects
(nZ30)
PAD
patients
(nZ51)
p
Age (years) 67.0G13.6 70.0G7.3 NS
Male gender (%) 70.0 84.3 NS
Hypertension (%) 56.7 72.5 NS
CAD (%) 20 49 0.009
Hypercholesterolemia (%) 13.3 35.3 0.032
Diabetes mellitus (%) 13.3 35.3 0.032
Smoking (%) 26.7 72.5 !0.001
Body mass index (kg/m2) 26.6G4.7 27.8G3.0 NS
Ankle–brachial index 1.01G0.08 0.47G0.19 !0.001
Statin use (%) 10 29.4 0.042
Values are meanGSD or percentages.three patients’ values, were above this limit. TNF-a
serum levels’ association with lower limb athero-
sclerosis was just outside the limit of statistical
significance (pZ0.055). On the contrary, anti-Cp IgA
showed a strong statistical correlation with PAD (p!
0.001). When all univariate associations were entered
into the multiple analysis, only smoking (pZ0.001),
CRP (pZ0.026) and anti-Cp IgA (pZ0.001) remained
independently associated with the disease.
Ankle–brachial index has shown many important
and strong negative associations with coronary artery
disease (pZ0.029), diabetes mellitus (pZ0.006),
hypercholesterolemia (pZ0.012), smoking (pZ0.004)
and statin use (pZ0.030). Apart from the traditional
risk factors ABI was also negatively correlated with
CRP (p!0.001) and anti-Cp IgA (p!0.001). On
multiple analysis, only diabetes mellitus (pZ0.008),
CRP (pZ0.041) and anti-Cp IgA (p!0.001) retained
their significance. IgA positive patients had a signifi-
cantly lower ABI (0.50G0.29), than IgA negative ones
(ABIZ0.79G0.26) (Table 4).
Group A patients had significantly higher CRP
(pZ0.014), fibrinogen (pZ0.032), TNF-a (pZ0.014) and
anti-Cp IgA (0.004) concentrations than group B
patients. We included in a multiple linear regression
analysis model, all the parameters that were signifi-
cantly associated with the more severe form of PAD.
The only ones that retained their association, were theTable 3. Inflammatory markers and Chlamydia pneumoniae
serology in PAD patients and controls
Control sub-
jects (nZ30)
PAD patients
(nZ51)
p
CRP (mg/dl) 0.76G0.57 3.54G4.17 0.001
Fibrinogen (mg/dl) 231.07G99.63 233.53G65.46 NS
VCAM-1 (ng/ml) 1030.0G194.3 1103.7G274.9 NS
TNF-a (pg/ml) 28.06G25.83 115.61G244.6 NS
Anti-Cp IgA (EIU/ml) 2.58G2.23 7.55G6.91 !0.001
Anti-Cp IgG (EIU/ml) 30.95G28.17 40.37G34.7 NS
Values are meanGSD.
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Table 4. Inflammatory markers and Chlamydia pneumoniae
serology in group A and B patients
Group A
(nZ28)
Group B
(nZ23)
p
CRP (mg/dl) 4.83G5.03 1.98G1.94 0.014
Fibrinogen (mg/dl) 251.18G69.58 212.04G54 0.032
VCAM-1 (ng/ml) 1143.9G308.2 1054.7G224.9 NS
TNF-a (pg/ml) 190.62G312.35 24.29G19.03 0.014
Anti-Cp IgA (EIU/ml) 9.88G8.05 4.71G3.68 0.004
Anti-Cp IgG (EIU/ml) 37.95G27.10 43.33G42.64 NS
Values are meanGSD.
Fig. 1. Box and whisker plot of CRP values in the three
groups. Box represents median and interquartile range and
whiskers the extreme values.
Fig. 2. Box and whisker plot of anti-Cp IgA values in the
three groups. Box represents median and interquartile range
and whiskers the extreme values.
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(pZ0.011). IgA positive patients had significantly
lower ABI (0.38G0.19) when compared to the IgA
negative ones (0.57G0.16).
Initial claudication distance for peripheral arterial
disease patients was significantly correlated with anti-
Cp IgA values and IgA seropositivity (p!0.001). IgA
negative patients had almost the double ICD (228.4G
87.7 m), compared to the IgA positive ones (122G
87.6 m). Only three out of 16 patients whose ICD was
greater than 250 m were positive, whereas nineteen
out of 23 were positive among those with ICD lower
than 170 m. Fibrinogen (pZ0.053) and TNF-a (0.074)
were also associated with the ICD but not to a
statistically significant degree. CRP levels were not
associated with the ICD nor with the ACD. Absolute
claudication distance was significantly correlated with
anti-Cp IgA (p!0.001) and fibrinogen (pZ0.049). ACD
in IgA positive claudicants (176.9G138.5 m) was
almost half that of IgA negative ones (346.4G149.1 m).
CRP values differed significantly between the three
groups as we can see in Fig. 1. There is a small overlap
between the groups but the differences in CRP
concentrations are statistically important both
between groups B and C patients (pZ0.002), and
between groups B and A patients (pZ0.014). Two
thirds of control patients had CRP levels below 1 mg/
dl, while the same percentage of group B and group A
patients had their CRP measured above 0.74 and
1.48 mg/dl, respectively.
Anti-Cp IgA levels were also gradually increased
across the groups from controls to group A patients, as
it is clearly shown in Fig. 2. Group B patients had
significantly higher anti-Cp IgA values compared to
control subjects (pZ0.023) and as we have already
seen group A patients had concentrations higher than
group B patients. Two out of three control subjects had
IgA values below 2.29 EIU/ml, while in groups A and
B, two thirds of the patients had values above 3.29 and
5.66 EIU/ml, respectively. Anti-Cp IgA concentrations
were higher in patients with advanced age (pZ0.031),
those with higher CRP (pZ0.008) and TNF-a values
(pZ0.011).Eur J Vasc Endovasc Surg Vol 31, May 2006Twenty-six out of 51 PAD patients were IgA
seropositive (51%) compared to only seven out of 30
control subjects (23.3%) and this difference was
statistically significant (pZ0.014) (Fig. 3). The odds
ratio for the prevalence of femoral atherosclerosis was
3.16 for IgA seropositive patients (CI 1.15–8.67). When
both IgA and CRP values were positive, the odds ratio
for the prevalence of PAD reaches 6.48 (CI 1.72–24).
Fig. 3. Chlamydia pneumoniae IgA seropositive patients in
PAD and control groups.
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significant association with peripheral arterial disease,
nor with its clinical severity.
Patients on statin use had lower CRP values
(pZ0.034), but the other inflammatory markers were
not affected. Statin use had no correlation with
C. pneumoniae serology or immunohistochemical detec-
tion of the pathogen in the atheroma, but did have a
strong statistical association with smoking (pZ0.007).
Out of the 28 plaque samples of patients of group A,
14 (50%) were positive on immunohistochemical
examination for the presence of C. pneumoniae.
Among the baseline characteristics only smoking had
a statistically significant correlation with C. pneumoniae
detection in the plaque (pZ0.043). No significant
associations were observed with disease distribution
and severity, ABI, ICD and ACD. Patients with
C. pneumoniae detection in the plaque had significantly
(pZ0.011) higher anti-Cp IgA levels (13.77G
8.80 EIU/ml), when compared to negative patients
(6.43G4.88 EIU/ml). TNF-a serum values were also
much higher in tissue positive patients (pZ0.008).
On multiple linear regression analysis anti-Cp IgA
(pZ0.023) and TNF-a (pZ0.031) retained their statisti-
cally significant correlation with C. pneumoniae iso-
lation in the atheroma. C. pneumoniae was detected in
only one of the 28 vein specimens (3.6%), taken from
the same patients.Discussion
Our results have demonstrated that peripheral arterial
disease patients had higher levels of CRP and anti-Cp
IgA than controls. This is in line with the findings of
Ridker et al.,12 who have shown that baseline levels of
CRP predict future risk of developing symptomatic
PAD. CRP has also been associated with plaque
density at the femoral level but not with intima-
media thickness (IMT).13 In another study, CRP was
the strongest univariate predictor of risk of PAD
development and had the greatest additive valuewhen combined with either total cholesterol (TC), or
the TC/HDL-C ratio.14 The results regarding anti-Cp
IgA antibodies are similar to those of Mayr et al.15
Bloemenkamp et al., demonstrated that among women
with a high CRP level, the odds ratio for PAD
increased with the number of infections.16
ABI and treadmill test are considered the most
objective measures of functional impairment of the
lower limbs.17 According to some authors, the constant
load treadmill test has a larger variability and a higher
coefficient of variation, compared to the graded tread-
mill test.6 Nevertheless, in the last TransAtlantic Inter-
society Consensus for the management of PAD, both
tests are acceptable as long as they are performed in a
rigorously controlled and standardized manner.18
The inverse association of CRP and ABI is
supported by several studies.19,20 Others have found
a statistically significant association that disappeared
after multivariant analysis.21 We did not find a
statistically significant correlation between CRP levels
and walking distances and this could relate to the type
of treadmill assessment used. Higher CRP levels, were
associated in one study with poorer 6-min walk
performance and a lower summary performance
score.22 Patients with greater endothelial dysfunction
have higher CRP and fibrinogen levels.23
The relationship of anti-Cp IgA antibodies with the
ABI is corroborated by the study of Lindholt et al.24
Wiesli et al.,25 found that in seropositive men suffering
from PAD, a 4-week regimen of roxithromycin, had a
long term beneficial effect both on their ABI and their
walking distance. A short 3-day course of azithromy-
cin, had no effect whatsoever on survival and ABI in
PAD patients, according to Vainas et al.26 Finally, in
another important study,10 improvement of ABI and
walking distance and the number of invasive revascu-
larizations per patient have been associated to C.
pneumoniae seropositivity, and a 4-week roxithromycin
course had long term positive effects on all these
parameters. Large scale, long term, randomized
controlled antibiotic trials, have shown no effect of
macrolides on adverse events or survival of coronary
artery disease patients.27
In our study, CRP and anti-Cp IgA levels were
associated with severe claudication. CRP levels of
critical limb ischemia patients have been found to be
higher, than in claudicants.28 In a larger study, Cassar
et al.29 have shown that claudicants have significantly
elevated levels of CRP, compared to controls and that
patients with critical ischemia have significantly
higher CRP values than claudicants. CRP and anti-
Cp IgA levels were directly correlated and this
supports even further our suggestion that inflamma-
tory response to Cp contributes to disease progression.Eur J Vasc Endovasc Surg Vol 31, May 2006
E. A. Kaperonis et al.514The detection of the Cp in half of the femoral
plaques and in only 3.6% of the veins, is similar to
previous studies. Linares-Palomino et al.,9 detected
bacterial DNA in 67% of the femoral atheromas and
4% of saphenous veins. In two other studies, pathogen
isolation in femoral plaques reached 47.4 and 59%.30,31
A weak correlation was found between seropositivity
and plaque infection, in the only study specific for
PAD patients.9
In our data, we have found a positive relation
between CRP, anti-Cp IgA seropositivity and the
presence and severity of lower limb atherosclerosis.
CRPhas alreadybeen shown tobe a sensitivemeasure of
generalized atherosclerosis and systemic atherosclerotic
burden.32 Since, IgA antibodies are a better markers of
chronicity of infection,33 an ongoing inflammatory-
infectious process, could lead to advanced lower limb
arterial disease. Because the study is cross sectional, its
power to prove causality is limited. In conclusion, our
findings suggest that inflammation and C. pneumoniae
infection have an important role in peripheral arterial
disease and are associated with disease severity.
Whether these are primary or secondary to the
atherosclerotic changes, remains to be proven.
Additional studies are needed to determine the mech-
anism of the associations reported here.References
1 Osler W. Diseases of the arteries. In: Osler W, ed. Modern
medicine: its practice and theory. Philadelphia: Lea and Febiger,
1908:429–447.
2 Hanson GK. Inflammation, atherosclerosis, and coronary artery
disease. N Engl J Med 2005;352:1685–1695.
3 Saikku P, LeinonenM,Matilla K, EkmanM-R,NieminenMS,
Makela PH et al. Serological evidence of an association of a novel
Chlamydia, TWAR, with chronic coronary heart disease and acute
myocardial infarction. Lancet 1988;2:983–986.
4 Engstrom G, Lind P, Hedblad B, Stavenow L, Janzon L,
Lindgarde F. Effects of cholesterol and inflammation-sensitive
plasma proteins on incidence of myocardial infarction and stroke
in men. Circulation 2002;105(22):2632–2637.
5 Wolf SC, Mayer O, Jurgens S, Vonthein R, Schultze G,
Risler T et al. Chlamydia pneumoniae IgA seropositivity is
associated with increased risk for atherosclerotic vascular
disease, myocardial infarction and stroke in dialysis patients.
Clin Nephrol 2003;59(4):273–279.
6 Hiatt WR, Hirsch AT, Regensteiner JG, Brass EP. Clinical
trials for claudication. Assessment of exercise performance,
functional status, and clinical end points. Vascular Clinical
Trialists. Circulation 1995;92(3):614–621.
7 Diehm C, Schuster A, Allenberg JR, Darius H, Haberl R,
Lange S et al. High prevalence of peripheral arterial disease and
co-morbidity in 6880 primary care patients: cross-sectional study.
Atherosclerosis 2004;172:95–105.
8 Signorelli SS, Mazzarino MC, Di Pino L, Malaponte G,
Porto C, Pennisi G et al. High circulating levels of cytokines (IL-
6 and TNF-a), adhesion molecules (VCAM-1 and ICAM-1) and
selectins in patients with peripheral arterial disease at rest and
after a treadmill test. Vasc Med 2003;8(1):15–19.Eur J Vasc Endovasc Surg Vol 31, May 20069 Linares-Palomino JP, Gutierrez J, Lopez-Espada C, de Dios
Luna J, Ros E,Maroto C. Genomic, serologic and clinical case–
control study of Chlamydia pneumoniae and peripheral artery
occlusive disease. J Vasc Surg 2004;40:359–366.
10 Krayenbuehl P-A,Wiesli P,Maly FE, VetterW, Schulthess G.
Progression of peripheral arterial occlusive disease is associated
with Chlamydia pneumoniae seropositivity and can be inhibited by
antibiotic treatment. Atherosclerosis 2005;179:103–110.
11 Grayston JT, Kronmal RA, Jackson LA, Parisi AF,
Muhlestein JB, Cohen JD et al. Azithromycin for the secondary
prevention of coronary events. N Engl J Med 2005;352:1637–1645.
12 Ridker PM, Cushman M, Stampfer MJ, Tracy RP,
Hennekens CH. Plasma concentration of C-reactive protein
and risk of developing peripheral vascular disease. Circulation
1998;97:425–428.
13 Muscari A, Martignani C, Bastagli L, Poggiopollini G,
Tomassetti V, Baldini L et al. A comparison of acute phase
proteins and traditional risk factors as markers of combined
plaque and intima-media thickness and plaque density in carotid
and femoral arteries. Eur J Vasc Endovasc Surg 2003;26:81–87.
14 Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for
systemic atherosclerosis: a comparison of C-reactive protein,
fibrinogen, homocysteine, lipoprotein(a), and standard choles-
terol screening as predictors of peripheral arterial disease. JAMA
2001;285(19):2481–2485.
15 Mayr M, Kiechl S, Willeit J, Wick G, Xu Q. Infections,
immunity, and atherosclerosis: associations of antibodies to
Chlamydia pneumoniae, Helicobacter pylori, and cytomegalovirus
with immune reactions to heat-shock protein 60 and carotid or
femoral atherosclerosis. Circulation 2000;102(8):833–839.
16 BloemenkampDG,MaliWP, Tanis BC,Rosendaal FR, van den
Bosch MA, Kemmeren JM et al. Chlamydia pneumoniae, Helico-
bacter pylori and cytomegalovirus infections and the risk of
peripheral arterial disease in young women. Atherosclerosis 2002;
163(1):149–156.
17 Izquierdo-Porrera AM, Gardner AW, Bradham DD,
Montgomery PS, Sorkin JD, Powell CC et al. Relationship
between objective measures of peripheral arterial disease
severity to self-reported quality of life in older adults with
intermittent claudication. J Vasc Surg 2005;41(4):625–630.
18 Management of peripheral arterial disease (PAD). TransAtlantic
Inter-society Consensus (TASC). Section B: intermittent claudica-
tion. Eur J Vasc Endovasc Surg 2000;19(Suppl A):S47–S114.
19 Langlois M, Duprez D, Delanghe J, De Buyzere M,
Clement DL. Serum vitamin C concentration is low
in peripheral arterial disease and is associated with inflam-
mation and severity of atherosclerosis. Circulation 2001;
103(14):1863–1868.
20 McDermott MM, Green D, Greenland P, Liu K, Criqui MH,
Chan C et al. Relation of levels of hemostatic factors and
inflammatory markers to the ankle brachial index. Am J Cardiol
2003;92(2):194–199.
21 Santos S, Rooke TW, Bailey KR, McConnell JP, Kullo IJ.
Relation of markers of inflammation (C-reactive protein, white
blood cell count, and lipoprotein-associated phospholipase A2)
to the ankle–brachial index. Vasc Med 2004;9(3):171–176.
22 McDermott MM, Greenland P, Green D, Guralnik JM,
Criqui MH, Liu K et al. D-dimer inflammatory markers, and
lower extremity functioning in patients with and without
peripheral arterial disease. Circulation 2003;107(25):3191–3198
[Epub 2003 January 16].
23 Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di
Donato A, Schiano V et al. Endothelial dysfunction in
peripheral arterial disease is related to increase in plasma
markers of inflammation and severity of peripheral circulatory
impairment but not to classic risk factors and atherosclerotic
burden. J Vasc Surg 2003;38(2):374–379.
24 Lindholt JS,Vammen S, Lind I, FastingH,Henneberg EW. The
progression of lower limb atherosclerosis is associated with IgA
antibodies againstChlamydia pneumoniae. Eur J Vasc Endovasc Surg
1999;18(6):527–529.
Inflammation, Infection and Peripheral Arterial Disease 51525 Wiesli P, Czerwenka W, Meniconi A, Maly FE, Hoffmann U,
VetterW et al. Roxithromycin treatment prevents progression of
peripheral arterial occlusive disease in Chlamydia pneumoniae
seropositive men: a randomized, double-blind, placebo-con-
trolled trial. Circulation 2002;105(22):2646–2652.
26 Vainas T, Stassen FR, Schurink GW, Tordoir JH,
Welten RJ, van den Akker LH et al. Secondary prevention
of atherosclerosis through Chlamydia pneumoniae eradication
(SPACE trial): a randomised clinical trial in patients with
peripheral arterial disease. Eur J Vasc Endovasc Surg 2005;
29(4):403–411.
27 Andraws R, Berger JS, Brown DL. Effects of antibiotic
therapy on outcomes of patients with coronary artery disease:
a meta-analysis of randomized controlled trials. JAMA 2005;
293(21):2641–2647.
28 Fiotti N, Giansante C, Ponte E, Delbello C, Calabrese S,
Zacchi T. Atherosclerosis and inflammation. Patterns of
cytokine regulation in patients with peripheral arterial disease.
Atherosclerosis 1999;145(1):51–60.
29 CassarK, Bachoo P, Ford I,GreavesM, Brittenden J. Markers
of coagulation activation, endothelial stimulation andinflammation in patients with peripheral arterial disease. Eur
J Vasc Endovasc Surg 2005;29(2):171–176.
30 Loehe F, Bittmann I, Weilbach C, Lauterjung L,
Schildberg FW, Heiss MM. Chlamydia pneumoniae in athero-
sclerotic lesions of patients undergoing vascular surgery. Ann
Vasc Surg 2002;16(4):467–473 [Epub 2002 July 8].
31 Gutierrez J, Linares-Palomino J, Lopez-Espada C,
Rodriguez M, Ros E, Piedrola G et al. Chlamydia pneumoniae
DNA in the arterial wall of patients with peripheral vascular
disease. Infection 2001;29(4):196–200.
32 Brevetti G, Piscione F, Silvestro A, Galasso G, DiDonato A,
Oliva G et al. Increased inflammatory status and higher
prevalence of three-vessel coronary artery disease in patients
with concomitant coronary and peripheral atherosclerosis.
Thromb Haemost 2003;89:1058–1063.
33 Ward ME. The immunobiology and immunopathology of
chlamydial infections. APMIS 1995;103:769–796.
Accepted 24 November 2005
Available online 19 January 2006Eur J Vasc Endovasc Surg Vol 31, May 2006
